Please login to the form below

Not currently logged in
Email:
Password:

Cimzia

This page shows the latest Cimzia news and features for those working in and with pharma, biotech and healthcare.

FCB Health Europe takes aim at strategy development

FCB Health Europe takes aim at strategy development

From there, Huzzey moved to UCB Biopharma in Belgium, where she worked initially as European brand lead for CIMZIA, before taking on a role in the UK as head of country

Latest news

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

  • NICE approves UCB Pharma’s Cimzia NICE approves UCB Pharma’s Cimzia

    NICE approves UCB Pharma’ s Cimzia. New guidance could significantly extend the patient population it could treat. ... Cimzia works by stopping the body's immune system attacking the joints - this in turn helps to reduce swelling and joint damage.

  • NICE set to recommend seven biologics for severe rheumatoid arthritis NICE set to recommend seven biologics for severe rheumatoid arthritis

    NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Specifically Cimzia, one of

  • NICE backs biosimilars in rheumatoid arthritis guidance NICE backs biosimilars in rheumatoid arthritis guidance

    The recommended brands are: AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB's Cimzia (certolizumab pegol), MSD/Johnson &Johnson's Simponi (golimumab), Roche's RoActemra (tocilizumab), Bristol-Myers Squibb's ... All the drugs are

More from news
Approximately 8 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • Investing in the future of R&D Investing in the future of R&D

    Funding growth . Looking to his company's current performance, Doliveux says UCB is now in “ an intense growth phase fuelled by Cimzia”.

  • Pharma deals during July 2014 Pharma deals during July 2014

    dermatology specialist Dermira to develop Cimzia for psoriasis in the US, Canada and the EU. ... Cimzia, a pegylated antibody fragment that blocks tumour necrosis factor alpha, is currently indicated for several disorders including Crohn's disease,

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • Pharma deals during November 2013 Pharma deals during November 2013

    Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics